iLite^® ADCC Effector (V)

BM5001

Designed to quantify ADCC activity mediated by FcγRIIIa (V158), this iLite^® effector cell line is ideal for use in bioassays assessing the functional activity of antibody therapeutics.

High sensitivity and large dynamic range
"Assay-ready" format for rapid and convenient use
Reproducible and biologically relevant results
Reduced assay variability and higher reproducibility compared to cells in culture
Normalization of cell counts and serum matrix effects using a second reporter gene

Add to quote

Product Overview

iLite® ADCC Effector FcγRIIIa (V) Assay Ready Cells are used for quantifying biological activity induced by pathway activation of therapeutic antibody drugs in an ADCC mechanism of action (MOA) assay.

The cells are based on a human T lymphocyte cell line, Jurkat (ATCC #TIB-152). They have been genetically engineered and optimized to express high levels of the Fc receptor FcRyIIIa (CD16) and the Firefly Luciferase (FL) reporter gene under the control of a proprietary chimeric promoter.

iLite® ADCC Effector FcγRIIIa (V) Assay Ready Cells are ideally matched to the iLite® ADCC target cells but can be run with any type of target cells inducing ADCC MOA.

The ATCC® TIB-152 cell line is used under a license from ATCC®

FOR RESEARCH USE ONLY

How it works

Principle of iLite® ADCC Bioassays

Our two-cell ADCC bioassays consist of target cells expressing the antigen under study and effector cells closely resembling the natural FcγRIIIa (CD16) signal transduction pathway. Target control cells that do not express the antigen are also available. The effector cells contain two luciferase genes: an inducible Firefly luciferase gene and a constitutively expressed Renilla luciferase gene used for control purposes.

Principle of iLite® ADCC Bioassays

A therapeutic antibody can bind to its antigen on the target cell surface. The fc-region of the antibody can bind to the FcγRIIIa receptor on the effector cells.

Principle of iLite® ADCC Bioassays

The antibody binding to the target and effector cells triggers a signal pathway in the effector cell, activating the Firefly luciferase gene. The strength of the resulting luciferase luminescence correlates with the antibody’s ability to activate ADCC.

What's in the box?

>250 µL of iLite® Assay Ready Cells suspended in cryoprotective medium.

Specifications

Product code	BM5001
Assay target	ADCC
Size	1 vial corresponding to one 96 well plate
Technology	Cell-based reporter gene assay
Detection system	Luminescence
Regulatory status	Research Use Only